Does Meridian Bioscience, Inc. (VIVO) Have What it Takes to be in Your Portfolio Wednesday?

Wednesday, November 23, 2022 02:37 PM | InvestorsObserver Analysts

Mentioned in this article

Does Meridian Bioscience, Inc. (VIVO) Have What it Takes to be in Your Portfolio Wednesday?

The 61 rating InvestorsObserver gives to Meridian Bioscience, Inc. (VIVO) stock puts it near the top of the Diagnostics & Research industry. In addition to scoring higher than 88 percent of stocks in the Diagnostics & Research industry, VIVO’s 61 overall rating means the stock scores better than 61 percent of all stocks.

VIVO has an Overall Score of 61. Find out what this means to you and get the rest of the rankings on VIVO!

See Full VIVO Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 61 means the stock is more attractive than 61 percent of stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Meridian Bioscience, Inc. Stock Today?

Meridian Bioscience, Inc. (VIVO) stock is trading at $31.95 as of 2:35 PM on Wednesday, Nov 23, an increase of $0.17, or 0.55% from the previous closing price of $31.77. The stock has traded between $31.72 and $32.00 so far today. Volume today is low. So far 62,902 shares have traded compared to average volume of 290,559 shares. Click Here to get the full Stock Report for Meridian Bioscience, Inc. stock.